Zydus Therapeutics Inc.
Clinical trials sponsored by Zydus Therapeutics Inc., explained in plain language.
US subsidiary of Zydus Lifesciences, developing pharmaceutical products.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Liver drug study seeks to understand how body processes medication in scarred livers Results expected Dec 2026 (estimated)
- New drug study aims to understand how liver disease affects medication Results expected Dec 2026 (estimated)
- Hope for liver disease: new drug trial targets PBC symptoms Results expected Apr 2027 (estimated)
-
New drug shows promise against fatty liver and scarring
Disease control CompletedThis phase 2b trial tested whether saroglitazar magnesium can help people with nonalcoholic steatohepatitis (NASH) and liver fibrosis. 189 adults took either a 2 mg or 4 mg dose of the drug or a placebo daily for several months. The main goal was to see if the drug could resolve …
Phase 2 • Sponsor: Zydus Therapeutics Inc. • Aim: Disease control
Last updated Sep 21, 2026 20:00 UTC
-
New drug shows promise for rare liver disease in Late-Stage trial
Disease control CompletedThis study tested a drug called saroglitazar magnesium in 196 adults with primary biliary cholangitis (PBC), a chronic liver disease. Participants either took the drug or a placebo to see if it improved liver function markers. The goal was to lower certain liver enzymes and bilir…
Phase 2/3 • Sponsor: Zydus Therapeutics Inc. • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC